Log in Free sign up

SQZ Biotechnologies (SQZ) News and press releases

News

From Benzinga Pro

SQZ Biotechnologies Q1 EPS $(0.75) Down From $(0.59) YoY

SQZ Biotechnologies (NYSE:SQZ) reported quarterly losses of $(0.75) per share. This is a 27.12 percent decrease over losses of $(0.59) per share from the same period last year.

74 Biggest Movers From Yesterday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers T Stamp Inc. (NASDAQ: IDAI) shares surged 123.8% to close at $4.70 on Thursday. Trust Stamp reported the launch of its Biometric Multi-Factor Authentication (Biometric MFATM) solution.

48 Stocks Moving In Thursday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers T Stamp Inc. (NASDAQ: IDAI) shares jumped 201% to $6.33. Trust Stamp reported the launch of its Biometric Multi-Factor Authentication (Biometric MFATM) solution.

Mid-Morning Market Update: Markets Open Higher; US Economy Contracts 1.4% In Q1

Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets

U.S. stocks traded higher this morning with the Dow Jones gaining 300 points on Thursday.

The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates

Biotech, Earnings, Large Cap, News, Penny Stocks, Guidance, Health Care, Contracts, Small Cap, FDA, Movers, Trading Ideas, General

Here's a roundup of top developments in the biotech space over the last 24 hours:

28 Stocks Moving in Thursday's Pre-Market Session

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers T Stamp Inc. (NASDAQ: IDAI) shares rose 103.3% to $4.27 in pre-market trading after gaining over 8% on Wednesday. Trust Stamp recently posted Q4 net sales of $2.1 million.

SQZ Biotechnologies Receives FDA Fast Track Designation for SQZ-PBMC-HPV for the Treatment of HPV16+ Tumors

Biotech, News, Penny Stocks, Health Care, FDA, General

SQZ Biotechnologies (NYSE: SQZ) received Fast Track Designation from he U.S. Food and Drug Administration (FDA) for its lead cell therapy candidate, SQZ-PBMC-HPV, for the treatment of HPV16+ advanced or metastatic solid tumors. SQZ-PBMC-HPV-101 is currently being investigated in the Phase 1/2 clinical study.

SQZ Biotechnologies Received FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors

News, Penny Stocks, FDA

SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the U.S.

Stocks That Hit 52-Week Lows On Wednesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

Wednesday's session saw 784 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Tuesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.

Stocks That Hit 52-Week Lows On Thursday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Thursday, 236 companies hit new 52-week lows.

Stocks That Hit 52-Week Lows On Wednesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Wednesday, 160 companies hit new 52-week lows.

SQZ Biotechnologies To Present eAPC Preclinical Data Apr. 12

Biotech, General

SQZ® eAPC Platform Demonstrates that mRNA-based Expression of Co-Stimulatory CD86 and Membrane-bound IL-2 and IL-12 Dramatically Increases Antigen-Specific CD8 T Cell Activity T Cell Responses Shown Across

SQZ Biotechnologies Highlights Publication Of Comprehensive Preclinical Research On Co.'s SQZ Tolerizing Antigen Carrier Platform

Biotech, News, FDA, General

Tolerizing Antigen Carriers (TACs) Shown Preclinically to Combat Autoimmunity Through Deletion of Autoreactive T Cells, Anergy and Induction of Regulatory T Cells that Facilitate Potent Bystander

SQZ Biotechnologies Announces $2M Grant From the National Institutes Of Health To Develop A Novel, Scalable Cell Replacement Therapy For Parkinson's Disease

SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it has been awarded a $2 million SBIR Phase II grant from the National

SQZ Biotechnologies's Return On Capital Employed Insights

According to Benzinga Pro data, during Q4, SQZ Biotechnologies (NYSE:SQZ) posted sales of $12.35 million. Earnings were up 47.34%, but SQZ Biotechnologies still reported an overall loss of $11.82 million.

SQZ Biotechnologies To Present New Enhanced APC Platform Preclinical Findings And ENVOY-001 Phase 1/2 Clinical Trial In Progress Poster At The American Association For Cancer Research 2022 Annual Meeting

News, FDA, Events

SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it will present new preclinical findings on the company's

Stocks That Hit 52-Week Lows On Tuesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

Tuesday's session saw 729 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Monday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Monday, 524 stocks hit new 52-week lows.

Press releases

From Benzinga Pro

SQZ Biotechnologies Announces Integrated Point-of-Care Cell Therapy Manufacturing System Demonstrated Comparable or Better Performance Than a More Conventional Clean Room-Based Process

Average Processing Time Per Batch Less Than 6 Hours – a 55% Reduction with Comparable or Improved Product Metrics First Clinical Use Planned for SQZ® TACs in Celiac Disease with IND Submission Anticipated in 1H

SQZ Biotechnologies Reports First Quarter 2022 Financial Results and Recent Portfolio Updates

Granted FDA Fast Track Designation for Lead APC Clinical Candidate Received FDA IND Clearance to Initiate Phase 1/2 Clinical Trial of Next Generation eAPC Therapeutic Candidate for HPV16+ Solid Tumors Published

SQZ Biotechnologies to Host Live & Virtual R&D Investor Event on May 19, 2022

SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the company will host a live R&D investor event with optional virtual

SQZ Biotechnologies Announces First Data Presentation on Non-Clinical Studies of Point-of-Care Manufacturing System and Collaboration with STEMCELL Technologies on Research-Use-Only System to Fuel Preclinical Research

SQZ's Point-of-Care (POC) Manufacturing Platform Shows Promising Results with Ability to Produce Cell Therapies at Scale in Under 10 Hours Co-Development of Research-Use-Only System with STEMCELL Technologies to Help

SQZ Biotechnologies to Present at Upcoming Investor Conferences

SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that Armon Sharei, Ph.D., Chief Executive Officer and Founder of SQZ

Thinking about buying stock in Innoviz Technologies, Better Therapeutics, Hilltop Holdings, SQZ Biotechnologies, or Companhia Energetica Minas Gerais ADR?

Opinion, Press Releases

NEW YORK, May 2, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INVZ, BTTX, HTH, SQZ, and CIG.

Thinking about buying stock in Pitney Bowes, SQZ Biotechnologies, Pinterest, Archer Aviation, or Blackboxstocks?

Opinion, Press Releases

NEW YORK, April 28, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PBI, SQZ, PINS, ACHR, and BLBX.

SQZ Biotechnologies Receives FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors

Designation Creates Potential to Bring Important New Therapy to Patients Earlier SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced

SQZ Biotechnologies Presents New eAPC Preclinical Data Demonstrating That Multiplexed mRNA Engineering of Immune Cells Increases Killer T Cell Activity In Vivo

SQZ® eAPC Platform Demonstrates that mRNA-based Expression of Co-Stimulatory CD86 and Membrane-bound IL-2 and IL-12 Dramatically Increases Antigen-Specific CD8 T Cell Activity T Cell Responses Shown Across

SQZ Biotechnologies to Present at Upcoming Investor Conferences

SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that Armon Sharei, Ph.D., Chief Executive Officer and Founder of SQZ

SQZ Biotechnologies Publishes Comprehensive Preclinical Research on SQZ® TAC Platform's Ability to Induce Multiple Key Mechanisms of Antigen-Specific Tolerance and Protect Against Type 1 Diabetes

Tolerizing Antigen Carriers (TACs) Shown Preclinically to Combat Autoimmunity Through Deletion of Autoreactive T Cells, Anergy and Induction of Regulatory T Cells that Facilitate Potent Bystander

SQZ Biotechnologies Announces $2 Million Grant From the National Institutes of Health to Develop a Novel, Scalable Cell Replacement Therapy for Parkinson's Disease

Project to Focus on Creating Dopamine-Producing Neurons Using Direct mRNA-based Reprogramming of Immune Cells SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple

SQZ Biotechnologies Reports Full Year 2021 Financial Results and Recent Portfolio Updates

SQZ-PBMC-HPV-101 Induced Radiographic, Symptomatic and Immune Response as Monotherapy in Post-Checkpoint HPV+ Solid Tumor Patient as Demonstrated in December 2021 ESMO-IO Oral Presentation DSMB Recommended

SQZ Biotechnologies to Present New Enhanced APC Platform Preclinical Findings and ENVOY-001 Phase 1/2 Clinical Trial in Progress Poster at the American Association for Cancer Research 2022 Annual Meeting

SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it will present new preclinical findings on the company's enhanced